On Thursday, Montrose Regional Health (MRH) announced that it is now offering DOTATATE PET/CET scans to better evaluate and ...

Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...

This opening segment establishes the clinical context for a 66 year old man with well differentiated, non functioning, ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...

Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators provide ...

The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...

The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo ...

After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...

Stage 1 lung carcinoid tumors are confined to the lung and have not spread to lymph nodes or distant organs. Tumors at this stage are typically small and localized, which often allows for curative ...